GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
0.4300
+0.0139 (3.34%)
At close: Jun 26, 2026, 4:00 PM EDT
0.4358
+0.0058 (1.35%)
After-hours: Jun 26, 2026, 7:53 PM EDT
GT Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
15.51M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 27.00K | -34.00K | -55.74% |
| Dec 31, 2014 | 61.00K | -307.00K | -83.42% |
| Dec 31, 2013 | 368.00K | 26.00K | 7.60% |
| Dec 31, 2012 | 342.00K | 316.00K | 1,215.38% |
| Dec 31, 2011 | 26.00K | 15.00K | 136.36% |
| Dec 31, 2010 | 11.00K | -37.00K | -77.08% |
| Dec 31, 2009 | 48.00K | -1.10M | -95.80% |
| Dec 31, 2008 | 1.14M | -581.00K | -33.70% |
| Dec 31, 2007 | 1.72M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGTBP News
- 9 days ago - GT Biopharma Proxy statement: Proxy filing - Filings
- 19 days ago - Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet - GlobeNewsWire
- 26 days ago - GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives - GlobeNewsWire
- 6 weeks ago - GT Biopharma Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 6 weeks ago - GT Biopharma Quarterly report: Q1 2026 - Filings
- 6 weeks ago - GT Biopharma Earnings release: Q1 2026 - Filings
- 6 weeks ago - GT Biopharma doses first patient in GTB-5550 trial - TheFly
- 6 weeks ago - GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors - GlobeNewsWire